Artificial intelligence (AI) is profoundly transforming the paradigm of solid tumor drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, AI has significantly accelerated the discovery and validation of new targets, compressing the traditional ten-year research and development cycle to two to three years. Generative AI platforms have optimized small molecule inhibitors, biologics, and messenger RNA vaccines, achieving breakthroughs in overcoming tumor heterogeneity, improving efficacy, and predicting drug resistance. However, clinical translation still faces challenges such as data bias, algorithm transparency, and the validation gap between models and real-world human experience. This review aims to systematically elaborate on the transformative role of AI in solid tumor drug development and to promote interdisciplinary cooperation as well as the construction of ethical frameworks to enable the full realization of precision oncology.

Scientists reengineered chemo drug into spherical nucleic acids (SNAs), a globular form of DNA. Team tested the repackaged therapy on an animal model of acute myeloid leukemia, a fast-moving blood cancer. SNAs easily entered cancer cells and killed them from the inside while sparing healthy cells.

Lithium-ion batteries power our phones, cars, and even homes; ensuring their safe and efficient behavior has become incredibly important. Using a simple optical technique, Purdue University researchers have observed a battery's individual particles lighting up as they charge - enabling a more complete picture of the battery's overall health and performance.